Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Lilly/Loxo Deal Came Together Quickly

Lilly's $8bn acquisition of genetics-based cancer specialist Loxo Oncology didn't involve any other bidders and was finalized in just days over the holidays as Lilly sought to make a news splash at the J.P. Morgan Healthcare conference, according to an SEC filing.

Deals Business Strategies Commercial

J&J’s Erleada Gives Chase To Xtandi For Non-Metastatic Prostate Cancer With Approval In Europe

Astellas/Pfizer’s Xtandi and Johnson & Johnson’s Erleada are both now approved for non-metastatic castration-resistant prostate cancer in Europe, while Xtandi benefits from physician familiarity, Erleada has shown greater metastasis-free survival.

Cancer Approvals Europe

Spectrum Reshuffles Focus, Selling Seven Products To Aurobindo

By selling seven approved oncology/hematology products to a US affiliate of Aurobindo, Spectrum gets cash to increase focus on late-stage candidates Rolontis for neutropenia and poziotinib for solid tumors.

Cancer Commercial Deals
Advertisement


 Recent Tweets from Scrip


Factoring the "What Ifs" into Supply Forecasting

With the pressure on to deliver new products faster and more efficiently, sponsors are facing a variety of challenges. Download this whitepaper and discover the challenges as well as aspects to consider when developing a supply plan, the influence of early decisions and much more.

Read Now

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

 

Commercial Explore this Topic

Set Alert for Commercial

Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks

Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.

Financing StartUps and SMEs Business Strategies

Otsuka, Click ‘Digital Therapeutic’ Alliance Aims At Novel Depression Option

“There’s an app for that” could take on added significance under a new alliance for a digital therapeutic for the treatment of depression, in which the partners hope the novel approach will take its place as an effective option among current drug and other cognitive therapies.

Digital Health Business Strategies Neurology

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Financing Business Strategies

US Army Splashes The Cash On Valneva's JE Vaccine

Valneva’s 2019 guidance has been boosted by the US Army’s Ixiaro vaccine order, as other products flourish in the pipeline.

Vaccines Deals

Biotech Showcase 2019: Takeda Establishes Digital Health Focused Fund

Digital health represents a set of opportunities that can transform all parts of the pharma landscape. Speaking on the sidelines of Biotech Showcase 2019, Stephanie Bova, managing partner at Hatch@Takeda, tells Scrip how the Japanese pharma has established a new group to support the creation and financing of digital health businesses in the US and Europe.

Financing Digital Health

How Lilly Aims To Make Sure Good Drugs Don't Get Lost In Translation

SVP/CSO Daniel Skovronsky says the company has invested in technology and biotech-like teams to speed up the process of translating targets identified in house into human data for novel drugs.

Business Strategies Research and Development Strategies

The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.

Market Access Pricing Strategies

Video: Novo Seeds Describes Company-Building Aspirations

With a focus on innovative early stage European biotechs, Novo Seeds senior partner Stephan Christgau explains to Scrip how the investor picks opportunities and creates companies.

Financing Companies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Financial Transparency Concerns Over Patient Groups Advising NICE

England and Wales' cost-effectiveness agency has been urged to review its disclosure policy in a BMJ report which calls on NICE to probe the financial transparency of patient organizations that contribute to reimbursement assessments.

Reimbursement United Kingdom Health Technology Assessment

Pharma Industry Holds Tight As Disorderly Brexit Approaches

A worst-case Brexit scenario – a disorderly one – has become more likely, making an already white-knuckled life sciences industry step up its preparations.

Brexit Trade

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants surveyed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies

Roche Calls For Harmonized Regulation As Subcutaneous Herceptin Is Denied Trial Waiver In India

Roche’s subcutaneous (SC) Herceptin (trastuzumab) has been declined a trial waiver in India, at least for now, stretching potential launch timelines for the product significantly. The company emphasizes that a harmonized regulatory approach could best serve patient interests for therapies like Herceptin that come with a ‘long history of proven efficacy’.

Policy & Regulation Clinical Trials

Research & Development Explore this Topic

Set Alert for Research & Development

Biotech Showcase 2019: Harnessing IgE Antibodies To Tackle Solid Cancers

Immuno-oncology is currently one of the hottest spaces for biotechs and so to rise above the noise companies need to be truly differentiated. Speaking on the sidelines of Biotech Showcase 2019, Tim Wilson, CEO of Cambridge, UK-based IGEM Therapeutics, tells Scrip how his company is achieving this by developing IgE antibody drugs to fight cancer, with its lead program against ovarian cancer already in Phase I testing.

ImmunoOncology Innovation Research & Development

United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa

It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.

Clinical Trials Research & Development

Aptinyx Says DPN Setback Just A Step In Seeking Chronic Pain Indication

Investors reacted negatively when Aptinyx’s lead candidate missed its primary endpoint in diabetic peripheral neuropathy, but CEO Riedel tries to emphasize the positives from the study while awaiting fibromyalgia data with NYX-2925.

Neurology Research & Development

Novartis R&D Chief Tsai On 2019 Goals, Priorities, BD And Digital Advances

R&D head John Tsai spoke with Scrip about culture change at Novartis as it moves toward advanced therapy platforms and embraces digital technologies, and offered a peek into what’s in store for R&D in 2019 and beyond.

Leadership Companies
UsernamePublicRestriction

Register

Advertisement